Authors: Bano T., Janahi E.M., Dhasmana A., Lohani M., Haque S., Mandal R.K., Dar S.A., Jawed A., Wahid M., Akhter N., Areeshi M.Y.
Author Affiliations: Bano, T., Environmental Carcinogenesis and Toxicoinformatics Laboratory, Department of Bioengineering and Biosciences, Integral University, Lucknow, Uttar Pradesh, India; Janahi, E.M., Department of Biology, College of Science, University of Bahrain, Bahrain; Dhasmana, A., Himalayan School of Biosciences and Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand, India; Lohani, M., Environmental Carcinogenesis and Toxicoinformatics Laboratory, Department of Bioengineering and Biosciences, Integral University, Lucknow, Uttar Pradesh, India, Department of Emergency Medical Sciences, College of Applied Medical Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Haque, S., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Mandal, R.K., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Dar, S.A., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Jawed, A., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Wahid, M., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia; Akhter, N., Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha, 65431, Saudi Arabia; Areeshi, M.Y., Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia
Publication Date: 2018
Purpose: The linkage of human T-cell leukemia virus type 1 (HTLV-1) to fatal diseases is a well known fact for many years. However, there has been no significant progress in the field of the treatment that can lead to the development of a successful vaccine. Furthermore, there are no means of assessing the risk of disease and its prognosis in the infected people. Methods: The current study has taken the cognizance of the importance of host’s immune response in reducing the risk of infectious diseases to carry out immunoinformatics driven epitope screening strategy of vaccine candidates against HTLV-1. In this study, a genetic variability and HLA distribution analysis among the documented HTLV-1 genotypes I, II, III, IV, V & VI was performed to ensure the coverage of the vast majority of population, where vaccine would be employed. The meticulous screening of effective dominant immunogens was done with the help of ABCPred and Immune Epitope Database. Results: The results showed that the identified epitopes might be protective immunogens with high conservancy and potential of inducing both protective neutralizing antibodies and T-cell responses. The peptides “PSQLPPTAPPLLPHSNLDHI”, “PCPNLVAYSSYHATY”, and “YHATYSLYLF”, were 100% conserved among different isolates from far and wide separated countries, suggesting negligible antigenic drift in HTLV-1. Conclusions: Overall, the mentioned epitopes are soluble, non-toxic suitable candidates for the development of vaccine against HTLV-1 and warrant further investigation and experimental validation. © 2018 Zerbinis Publications. All Rights Reserved.
Eshan2020-11-28T18:20:35+00:00
